Angela M DeMichele, MD MSCE

faculty photo
Alan and Jill Miller Professor in Breast Cancer Excellence
Co-Leader, Breast Cancer Program, Abramson Cancer Center, University of Pennsylvania
Physician Leader, Breast Cancer Clinical Research Unit, Abramson Cancer Center, University of Pennsylvania
Co-Director, 2-PREVENT Breast Cancer Translational Center of Excellence, Abramson Cancer Center, University of Pennsylvania
Department: Medicine

Contact information
Division of Hematology Oncology
Perelman Center for Advanced Medicine
10th Floor, South Pavilion
Office #10-153
3400 Civic Center Boulevard
Philadelphia, PA 19104
Office: 215-349-5730
Fax: 215-615-3349
B.A. (Biochemistry)
Brown University, 1988.
M.D. (Medicine)
Washington University School of Medicine, 1991.
M.S.C.E. (Clinical Epidemiology)
University of Pennsylvania, School of Medicine, 2001.
Permanent link
> Perelman School of Medicine   > Faculty   > Details

Description of Research Expertise

breast cancer, biomarkers, clinical trials, pharmacogenetics, cytokines, host immunogenetics, cancer survivorship, molecular epidemiology

Description of Clinical Expertise

breast cancer, neoadjuvant therapy, menopausal symptoms related to cancer, cancer survivorship

Selected Publications

Thakran S, Cohen E, Jahani N, Weinstein S.P, Pantalone L, Hylton N, Newit D, DeMichele A, Davatzikos C, Kontos D.: Impact of deformable registration methods for prediction of recurrence free survival response to neoadjuvant chemotherapy in breast cancer: Results from the ISPY 1/ACRIN 6657 trial. Transl Oncol. Page: 20:101411, Jun 2022.

Makhlin I, DeMichele A.: Trastuzumab deruxtecan: An antibody-drug conjugate embracing its destiny in breast cancer. Cell Rep Med. 3(6): 100668, June 2022.

Cristofanilli M, Rugo H.S, Im S.A, Slamon D.J, Harbeck N, Bondarenko I, Masuda N, Colleoni M, DeMichele A, Loi S, Iwata H, O'Leary B, André F, Loibl S, Bananis E, Liu Y, Huang X, Kim S, Lechuga Frean M.J, Turner N.C. : Overall Survival With Palbociclib And Fulvestrant in Women With HR+/HER2- ABC: Updated Exploratory Analyses of PALOMA-3, a Double-Blind, Phase 3 Randomized Study. Clin Cancer Res. May 2022 Notes: online ahead of print.

Martei Y.M, Narasimhamurthy M, Setlhako D.I, Ayane G, Ralefala T, Chiyapo S, Gross R, Shulman L.N, Grover S, DeMichele A.: Relative Dose Intensity and Pathologic Response Rates in Patients With Breast Cancer and With and Without HIV Who Received Neoadjuvant Chemotherapy. JCO Glob Oncol. Page: e2200016. May 2022.

Brown J.C, Sturgeon K, Sarwer D.B, Troxel A.B, DeMichele A.M, Denlinger C.S, Schmitz K.H.: The effects of exercise and diet on sex steroids in breast cancer survivors. Endocr Relat Cancer. May 2022 Notes: online ahead of print.

Meric-Bernstam F, Tannir NM , Lliopoulos O, Lee RJ, Lee ML, Fan AC, DeMichele A, Haas NB, Patel MR, Harding JJ, Voss MH, Owonikoko TK, Carthon B, Srinivasan R, Bendell JC, Jenkins Y, Whiting SH, Orford K, Bennett MK & Bauer TM: Telaglenastat Plus Cabozantinib or Everolimus For Advanced or Metastatic Renal Cell Carcinoma: an Open-Label Phase 1 Trial. Clin Cancer Res Feb 2022 Notes: Online ahead of print

Cescon DW, Kalinsky K, Parsons HA, Smith KL, Spears PA, Thomas A, Zhao F & DeMichele A: Therapeutic Targeting of Minimal Residual Disease to Prevent Late Recurrence in Hormone-Receptor Positive Breast Cancer: Challenges and New Approaches. Front Oncol. 11(10), Feb 2022.

Mayer EL, Fesl C, Hlauschek D, Garcia-Estevez L, Burstein HJ, Zdenkowski N, Wette V, Miller KD, Balic M, Mayer IA, Cameron D, Winer EP, Ponce Lorenzo, J J, Lake D, Pristauz-Telsnigg G, Haddad TC, Shepherd L, Iwata H, Goetz M, Cardoso F, Traina TA, , Sabanathan D, Breitenstein U, Ackerl K, Filho OM, Zehetner K, Solomon K, El-Abed S, Theall KP, Ray-Lu D, Dueck A, Gnant M, DeMichele A.: Treatment Exposure and Discontinuation in the PALbociclib CoLlaborative Adjuvant Study of Palbociclib With Adjuvant Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer (PALLAS/AFT-05/ABCSG-42/BIG-14-03). J Clin Oncol. 10(40): 449-458, Feb 2022.

Pfeiler G, DeMichele A, Dueck AC, Fesl C, Gnant M, & Mayer EL. : Safety of adjuvant CDK4/6 inhibitors during the COVID-19 pandemic. Lancet Oncol. 23(2): 195-197, Feb 2022.

Gnant M, Dueck AC, Frantal S, Martin M, Burstein HJ, Greil R, Fox P, Wolff A C, Chan A, Winer EP, Pfeiler G, Miller KD, Colleoni M, Suga J M, Rubovsky G, Bliss JM, Mayer, IA, Singer CF, Nowecki Z, Hahn O, Thomson J, Wolmark N, Amillano K, Rugo HS, Steger GG, Aranguiz B, Hadad T, Perello A, Bellet M, Fohler H, Filho O, Halper A, Solomon K, Schurmans C, Theall KP, Lu DR, Tenner K, Fesl K, DeMichele A, Mayer E, PALLAS groups and investigators : Adjuvant Palbociclib for Early Breast Cancer: The PALLAS Trial Results (ABCSG-42/AFT-05/BIG-14-03). J Clin Oncol Jan 2022 Notes: Online ahead of print

back to top
Last updated: 06/23/2022
The Trustees of the University of Pennsylvania